Kainos Medicine Inc

XKRX:284620 (Korea (the Republic of))  
â‚© 4675.00 (+2.07%) Jun 19
At Loss
P/B:
13.80
Market Cap:
â‚© 129.38B ($ 93.50M)
Enterprise V:
â‚© 115.50B ($ 83.47M)
Volume:
122.17K
Avg Vol (2M):
614.51K
Trade In:
Volume:
122.17K
At Loss
Avg Vol (2M):
614.51K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Kainos Medicine Inc ( XKRX:284620 ) from 2018 to Jun 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Kainos Medicine stock (XKRX:284620) PE ratio as of Jun 20 2024 is 0. More Details

Kainos Medicine Inc (XKRX:284620) PE Ratio (TTM) Chart

To

Kainos Medicine Inc (XKRX:284620) PE Ratio (TTM) Historical Data

Total 1287
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Kainos Medicine PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-20 At Loss 2024-04-12 At Loss
2024-06-19 At Loss 2024-04-11 At Loss
2024-06-18 At Loss 2024-04-09 At Loss
2024-06-17 At Loss 2024-04-08 At Loss
2024-06-14 At Loss 2024-04-05 At Loss
2024-06-13 At Loss 2024-04-04 At Loss
2024-06-12 At Loss 2024-04-03 At Loss
2024-06-11 At Loss 2024-04-02 At Loss
2024-06-10 At Loss 2024-04-01 At Loss
2024-06-07 At Loss 2024-03-29 At Loss
2024-06-05 At Loss 2024-03-28 At Loss
2024-06-04 At Loss 2024-03-27 At Loss
2024-06-03 At Loss 2024-03-26 At Loss
2024-05-31 At Loss 2024-03-25 At Loss
2024-05-30 At Loss 2024-03-22 At Loss
2024-05-29 At Loss 2024-03-21 At Loss
2024-05-28 At Loss 2024-03-20 At Loss
2024-05-27 At Loss 2024-03-19 At Loss
2024-05-24 At Loss 2024-03-18 At Loss
2024-05-23 At Loss 2024-03-15 At Loss
2024-05-22 At Loss 2024-03-14 At Loss
2024-05-21 At Loss 2024-03-13 At Loss
2024-05-20 At Loss 2024-03-12 At Loss
2024-05-17 At Loss 2024-03-11 At Loss
2024-05-16 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-02-29 At Loss
2024-05-07 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-08 At Loss
2024-04-16 At Loss 2024-02-07 At Loss
2024-04-15 At Loss 2024-02-06 At Loss

Kainos Medicine Inc (XKRX:284620) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Kainos Medicine Inc conducts research and develops medicines used to treat brain diseases, cancers, and infectious diseases.